ALK Rearrangement and Overexpression

Overview

According to the document, the ALK gene encodes the ALK receptor tyrosine kinase, a protein that transmits signals from the cell surface into the cell through signal transduction (page 2). When the ALK gene undergoes structural changes, known as ALK fusion or ALK rearrangement, it fuses with another partner gene, such as EML4, forming an abnormal fusion protein. This altered protein continuously activates growth pathways, driving cancers such as non-small cell lung cancer (NSCLC), neuroblastoma, and anaplastic large cell lymphoma (ALCL) (pages 2–3).

The diagram on page 4 visually shows different ALK fusion partners across diseases, including NPM1, TPM3, VCL, and KIF5B. Page 5 further illustrates how ALK rearrangements activate pathways like RAS/ERK and PI3K/AKT, leading to persistent oncogenic signaling. The document highlights that detecting these abnormalities through tests such as IHC, FISH, RT-PCR, and NGS is essential for diagnosis, therapeutic decision-making, and eligibility for ALK-targeted therapies.

Symptoms

While ALK rearrangement is a molecular event, the clinical symptoms arise from the cancers driven by this alteration. According to the indications and disease associations listed (pages 6 and 12):

Symptoms Suggesting ALK Rearrangement in Lung Cancer

1. Persistent cough
2. Chest discomfort
3. Shortness of breath
4. Fatigue
5. Unexplained weight loss

These symptoms correlate with ALK-positive NSCLC, especially in younger patients or non-smokers.

Symptoms in Anaplastic Large Cell Lymphoma (ALCL)

1. Enlarged lymph nodes
2. Fever
3. Night sweats
4. Weight loss

The document states that ALK-positive ALCL carries a significantly better prognosis (page 13).

Symptoms in Other ALK-Associated Tumors

1. Pain or mass lesions (e.g., inflammatory myofibroblastic tumor)
2. Neurological symptoms in neuroblastoma
3. Localized organ-specific symptoms depending on tumor site

These symptoms guide clinicians to investigate ALK rearrangement using molecular techniques.

Causes

Based on the detailed mechanistic explanation (pages 2–5), the causes of ALK rearrangement and overexpression include:

1. Chromosomal Breakage and Fusion

Chromosomal rearrangements at 2p23 result in ALK joining with partner genes, producing fusion proteins that send uncontrolled growth signals (page 3).

2. EML4-ALK Fusion

The most common mechanism in NSCLC (page 5). EML4 dimerizes ALK kinase, causing persistent activation.

3. Constitutive Activation

Fusion proteins activate ALK kinase without regulatory control, leading to continuous oncogenic signaling (page 5).

4. Abnormal Signaling Pathways

Activated pathways such as RAS/ERK and PI3K/AKT promote tumor cell survival, proliferation, and metastasis (page 5).

5. Gene Amplification & Mutations

As described on page 9, apart from rearrangements, ALK abnormalities may involve amplification or point mutations detectable by advanced molecular tests.

Risk Factors

The document outlines clinical, genetic, and pathological factors that increase the likelihood of ALK rearrangement:

1. Specific Cancer Types

(Page 12)

1. NSCLC (particularly adenocarcinoma with EML4 fusion)
2. ALCL (NPM1 fusion)
3. Neuroblastoma
4. Inflammatory myofibroblastic tumor
5. Renal cell carcinoma
6. Breast cancer
7. Spitzoid tumors

2. Younger Age & Non-Smoker Status

The prognostic notes (page 13) mention ALK-positive lung cancer commonly appearing in younger, non-smoking individuals.

3. Tumor Aggressiveness

The document describes ALK-driven cancers as often exhibiting aggressive behavior if untreated (page 13).

4. Genetic Susceptibility

The presence of ALK gene partners listed in the table (page 12) suggests underlying genomic vulnerability.

5. Clinical Scenarios Requiring ALK-Targeted Therapy

NSCLC patients being screened for ALK inhibitors such as crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib fall into this category (page 6).

Prevention

Prevention in the context of ALK rearrangement focuses on preventing diagnostic delays, ensuring accurate testing, and avoiding pre-analytical errors, rather than preventing the genetic event itself.

1. Correct Sample Collection

(Page 7)

1. Bone marrow aspiration
2. Tissue biopsy
3. Body fluids
4. EDTA blood samples (lavender capped)

2. Proper Storage & Transport

(Page 8)

1. Maintain ambient temperature
2. Deliver samples within 8 hours
3. Include bone marrow smears when applicable
4. Submit a completed surgical pathology request form

3. Use of Appropriate Diagnostic Methods

(Page 9–11)

1. IHC for screening
2. FISH for confirming fusion
3. RT-PCR for known variants
4. NGS for broad mutation detection

Selecting the correct method prevents misdiagnosis.

4. Monitoring Treatment Response

(Page 6 & 13)

Long-term monitoring helps detect resistance mutations and guides therapy adjustments.

5. Clinical Trial Evaluation

Identifying ALK status early supports patient eligibility for trials involving novel ALK inhibitors, helping prevent disease progression.